Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MANIDIPINO AUROVITAS 20 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/MANIDIPINO AUROVITAS 20 MG COMPRIMIDOS EFG

Approved

STANDARD

MANIDIPINO AUROVITAS 20 MG COMPRIMIDOS EFG

Aurovitas Spain, S.A.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 27, 2023
Approval ID: d4f504cdf7b2110e
Company: Aurovitas Spain, S.A.U.
Type: Standard

Approval Details

Approval Id: d4f504cdf7b2110e
Drug Cima Aemps Name: MANIDIPINO AUROVITAS 20 MG COMPRIMIDOS EFG
Register Number: 88816
Holder Company Name: Aurovitas Spain, S.A.U.
Marketing Company Name: Aurovitas Spain, S.A.U.
Authorization Date: 2023-04-27
Dosage Form: COMPRIMIDO
Dose: 20 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Aurovitas Spain, S.A.U.

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 27, 2023

Approval ID

d4f504cdf7b2110e

Type

Standard

Back to CIMA-AEMPS Approvals